IPO - Xilio Therapeutics, Inc.

Form Type: 424B5

Filing Date: 2025-06-03

Corporate Action: Ipo

Type: New

Accession Number: 000119312525133768

Filing Summary: On June 3, 2025, Xilio Therapeutics, Inc. filed a prospectus supplement related to the offering of pre-funded warrants and associated common stock warrants. The offering includes 66,676,000 shares of common stock at a combined offering price of $0.7499 per pre-funded warrant, which has an exercise price of $0.0001 and is immediately exercisable. Series A, B, and C warrants accompany the pre-funded warrants, all of which are structured to facilitate an offering to investors. The Series A warrants expire after five years with an exercise price of $0.75, while the Series B and C warrants have specific expiration dates and price adjustments based on market conditions. Xilio Therapeutics aims to use the proceeds from this offering to advance the development of its product candidates and for general corporate purposes. Additionally, the company is identified as an emerging growth company and smaller reporting company, allowing it to take advantage of certain regulatory exemptions.

Form Type: DEFA14A

Filing Date: 2025-06-03

Corporate Action: Ipo

Type: New

Accession Number: 000119312525133778

Filing Summary: On June 3, 2025, Xilio Therapeutics, Inc. supplemented its previously filed Proxy Statement dated April 28, 2025, regarding the annual meeting of stockholders scheduled for June 10, 2025. This supplement addresses the company's public offering of pre-funded warrants, Series A, B, and C warrants related to the purchase of common stock. The underwriting agreement with Leerink Partners was entered into on June 2, 2025, facilitating the offering of 66,676,000 shares with an estimated net income of approximately $46.6 million from the offering, post-underwriting costs. The document also outlines the various conditions regarding the exercise of these warrants, particularly the requirement for stockholder approval to increase authorized shares prior to their exercise. The offering is expected to close on June 5, 2025, contingent on customary closing conditions.